UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 39,772 Shares of IQVIA Holdings Inc. (NYSE:IQV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,226,083 shares of the medical research company’s stock after purchasing an additional 39,772 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.68% of IQVIA worth $290,545,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. PGGM Investments grew its holdings in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares during the last quarter. Simplify Asset Management Inc. increased its holdings in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Raymond James & Associates raised its position in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after purchasing an additional 5,417 shares during the last quarter. Versor Investments LP acquired a new position in IQVIA during the 3rd quarter worth $1,328,000. Finally, Gradient Investments LLC increased its stake in shares of IQVIA by 15.6% in the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock valued at $9,600,000 after buying an additional 6,134 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Robert W. Baird lowered their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Barclays dropped their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Down 0.2 %

Shares of NYSE:IQV opened at $200.96 on Friday. The firm has a market cap of $36.47 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company’s fifty day simple moving average is $218.67 and its 200 day simple moving average is $226.20. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.